Ribapak and Tremor - a phase IV clinical study of FDA data

Summary:

Tremor is reported as a side effect among people who take Ribapak (ribavirin), especially for people who are female, 50-59 old, have been taking the drug for 1 - 6 months also take Pegasys, and have Hepatitis c.

The phase IV clinical study analyzes which people have Tremor when taking Ribapak. It is created by eHealthMe based on reports of 3,390 people who have side effects when taking Ribapak from the FDA, and is updated regularly.

What is Ribapak?

Ribapak has active ingredients of ribavirin. eHealthMe is studying from 3,392 Ribapak users. Check the latest studies of Ribapak.

What is Tremor?

Tremor (trembling or shaking movements in one or more parts of your body) is found to be associated with 2,643 drugs and 3,728 conditions by eHealthMe. Check the latest studies of Tremor.

On Jul, 16, 2026

3,390 people reported to have side effects when taking Ribapak.
Among them, 40 people (1.18%) have Tremor.

Among these 40 people:

How long have people been on Ribapak when they have Tremor? *

What is the gender of people who have Tremor when taking Ribapak? *

female: 57.5 %
male: 42.5 %

What is the age of people who have Tremor when taking Ribapak? *

What are other drugs people take besides Ribapak? *

What are other side effects people have besides Tremor? *

Nausea (feeling of having an urge to vomit): 18 people, 45.00%
Fatigue (feeling of tiredness): 17 people, 42.50%
Headache (pain in head): 15 people, 37.50%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 14 people, 35.00%
Dyspnea (difficult or laboured breathing): 11 people, 27.50%
Nausea And Vomiting: 9 people, 22.50%
Insomnia (sleeplessness): 9 people, 22.50%
Weakness: 8 people, 20.00%
Memory Loss: 7 people, 17.50%
Thrombocytopenia (decrease of platelets in blood): 7 people, 17.50%

What are the existing conditions these people have? *

Hepatitis C: 25 people, 62.50%
Pain: 2 people, 5.00%
Osteoporosis (bones weak and more likely to break): 1 person, 2.50%
Neuromyelitis Optica (inflammation and demyelination of the optic nerve (optic neuritis) and the spinal cord (myelitis)): 1 person, 2.50%
Depression: 1 person, 2.50%
Demyelination (loss of the myelin covering of some nerve fibres resulting in their impaired function): 1 person, 2.50%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 1 person, 2.50%

* Approximation only. Some reports may have incomplete information.

Do you take Ribapak and have Tremor?

- Check whether Tremor is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ribapak:

Ribapak (3,392 reports)

Tremor treatments and more:

Tremor (195,267 reports)

Browse all side effects of Ribapak:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Tremor:

Tremor (2,643 drugs)

Browse all the conditions that are associated with Tremor:

Tremor (3,728 conditions)

Related publications that referenced our studies

Lin SY, Lin CL, Ju SW, Wang IK, Lin CC, Lin CH, Hsu WH, Liang JA, "Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study", PloS one, 2017 Mar .
Lin SY, Lin CL, Ju SW, Wang IK, Lin CC, Lin CH, Hsu WH, Liang JA, "Increasing risk of cataract in HCV patients receiving anti-HCV therapy: A nationwide cohort study", PloS one, 2017 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on ribavirin (the active ingredients of Ribapak) and Ribapak (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.